63 results
6-K
EX-99.1
SNY
Sanofi
25 Apr 24
Sales growth of 6.7% at CER and business EPS(1) of €1.78
10:49am
balance
Ambition of 50% of women in senior leadership roles by 2025
Ambition of 40% of women in executive roles by 2025
Engagement with communities
6-K
EX-99.1
SNY
Sanofi
1 Feb 24
Sanofi Delivers Solid Sales and Business EPS Growth at CER Amidst Successful Product Launches and Advancements in Immunology Pipeline
9:45am
roles by 2025
Engagement with communities
Engage socially and economically with all communities where we operate
12,240 volunteers
75,376 hours
6,825
6-K
EX-99.5
SNY
Sanofi
20 Dec 23
Current report (foreign)
10:39am
in remote health settings. This research, training, and community engagement experience is essential to run the clinical trial in remote settings
6-K
EX-99.1
SNY
Sanofi
27 Oct 23
Specialty Care growth, strong launch uptake of Beyfortus® and ALTUVIIIO® drive solid Q3 results
12:39pm
in executive posts by 2025
Engagement with communities
Engage socially and economically with all communities where we operate
5,905 volunteers
36,746 hours
6-K
EX-99.1
SNY
Sanofi
28 Jul 23
Solid Q2 performance and strong pipeline momentum
3:35pm
senior leaders were women
Engagement with communities
FY 2022
Q2 2023
# volunteers
4,975 volunteers
2,883 volunteers
# hours
26,906 hours
18,103 hours
6-K
EX-99.1
izkx8f ovz
27 Apr 23
Strong Q1 growth driven by Specialty Care, Vaccines and CHC
11:39am
6-K
EX-99.1
xk9kercgg7x3fde
28 Oct 22
Continued strong growth in Q3 with key regulatory milestones achieved
11:16am
6-K
EX-99.1
89yz9dv
28 Jul 22
Strong execution in Q2 drives full-year 2022 guidance upgrade and delivers rich R&D news flow in Immunology and Rare Disease
10:12am
6-K
EX-99.2
xs0cdyzubzjqja
28 Jul 22
Condensed Half-year Consolidated Financial Statements
6:17am
6-K
EX-99.2
wobng9llzy1 emqa
13 Jun 22
FDA approves Dupixent® (dupilumab) as first biologic medicine for children aged 6 months to 5 years with moderate-to-severe atopic dermatitis
2:56pm
6-K
EX-99.1
xzgxnw
28 Apr 22
Sanofi continues to deliver strong business EPS(1) growth driven by higher sales and improved margins in Q1
12:16pm
6-K
EX-99.1
1qoh2tnwn
4 Apr 22
Distribution of Shares of Euroapi
11:21am
6-K
EX-99.1
4ivk6cj2
4 Feb 22
Strong 2021 sales and business EPS(1) growth enabling increased investment in R&D
9:56am
6-K
EX-99.1
1bpeav6x
29 Jul 21
Sales growth accelerated - Full-year guidance raised
9:52am
6-K
EX-99.1
v7w m5823
16 Jul 21
Sanofi announces Paris 2024 Premium partnership for the Olympic and Paralympic Games in Paris
12:06pm
6-K
EX-99.1
ru3eqfc
18 Dec 20
Sanofi renews partnership with the WHO to fight Neglected Tropical Diseases and eliminate sleeping sickness before 2030
2:13pm